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The molecular events mediating the immunomodulatory properties of cannabinoids have 
remained largely unresolved. We have therefore investigated the molecular mechanism(s) 
through which R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl] pyrrolo[1,2,3-de]-1,4-
benzoxazinyl]-(1-napthanlenyl) methanone (WIN55212-2) modulate production of interleukin-8 
(IL-8) in HT-29 cells. Release of IL-8 induced by tumor necrosis factor-α (TNF-α) was 
determined by enzyme-linked immunosorbent assay (ELISA). Changes in expression of 
inhibitory kappa B (IκB) were monitored by Western blotting and activation of nuclear factor-
kappa B (NF-κB) was determined in electrophoretic mobility shift assay (EMSAs). TNF-α 
induced release of IL-8 was inhibited by WIN55212-2 which also blocked the degradation of 
IκB-α and activation of NF-κB induced by TNF-α. These data provide strong evidence that 
WIN55212-2 may modulate IL-8 release by negatively regulating the signaling cascade leading 
to the activation of NF-κB. These findings highlight a potential mechanism for the 
immunomodulatory properties of cannabinoids and contribute towards acquiring a clear 
understanding of the role of cannabinoids in inflammation.  
  




Pro-inflammatory cytokines are pivotal for the development of an inflammatory response 
and therefore constitute a pharmacological target for the development of anti-inflammatory 
therapies. In particular, the chemoattractant cytokine interleukin-8 (IL-8; now referred to as 
CXCL8) is essential for the recruitment of immune cells to the site of inflammation and for a 
coordinated immune response ( Miller and Krangel, 1992; Baggiolini et al., 1997). 
 Because of their immunomodulatory properties, therapeutic use of cannabinoids 
could provide new approaches for the development of anti-inflammatory therapies. However, 
although many immunosuppressive as well as some immunostimulatory effects are documented 
(Croxford and Yamamura, 2005), and cannabinoids historically have been used as anti-
inflammatory agents, the molecular mechanisms underlying these effects are poorly understood. 
Cannabinoids may however modulate immune responses by regulating the cytokine system 
(Klein et al., 1998), and this may be due in part to their ability to regulate signal transduction 
pathways associated with gene transcription and subsequent expression of immune cytokines. In 
this regard, cannabinoids have been reported to down regulate the adenylate cyclase  (AC) 
cascade, which is thought to be the main signal transduction pathway implicated in the immune 
response (Schatz et al., 1992;  Diaz et al., 1993; Kaminski et al.,1994; Kaminski, 1998). 
Inhibition of AC and thus of cAMP production may consequently inhibit protein kinase A 
(PKA), and hence phosphorylation of several downstream targets including the cAMP-response 
element binding protein/activation transcription factor (CREB/ATF) and NF-κB ( Herring et al., 
1998; Herring and Kaminski, 1999), thus suppressing the inflammatory process. 
Epithelial cells are an important component of the mucosal immune system, performing a 
variety of immune functions, including the expression of adhesion molecules and the secretion of 
cytokines (Schuerer-Maly et al., 1994). This central role and their proximity to the intestinal 
lumen make these cells easily accessible to pharmacological agents, and modulation of their 
activities is of major therapeutic importance in inflammation. In this report, we have therefore 
used the human HT-29 colon epithelial cell line to examine the molecular mechanism by which 
cannabinoids may regulate cytokine release. The studies have focused on the potent cannabinoid 
CB1/CB2 receptor agonist R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl] pyrrolo[1,2,3-
de]-1,4-benzoxazinyl]-(1-napthanlenyl) methanone mesylate (WIN55212-2) which has 
previously been shown to inhibited tumor necrosis factor-α (TNF-α) induced release of IL-8 via 
an action on the cannabinoid CB2 receptors. The latter conclusion was based partly on functional 
studies where WIN55212-2 induced inhibition of IL-8 release was reversed by the cannabinoid 
CB2 receptor antagonist [N-[(1S)-endo-1,3,3,-trimethyl-bicyclo[2,2,1]heptan-2-yl]-5-(4-chloro-3-
methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide] (SR144528), but not by the CB1 
receptor antagonist [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorphenyl)-4-methyl-H-
pyrazole-3 carboxyamidehydrochloride] (SR141716A) and partly on data from Western blot 
analysis using a polyclonal antibody raised against the amino terminus of the cannabinoid CB2 
receptor (Ihenetu et al., 2003a).   
 
Since IL-8 release may require de novo synthesis and thus gene transcription, our studies 
have focused on establishing whether NF-κB may be involved in this process and, more 
importantly, whether cannabinoids may be able to modulate IL-8 release through regulation of 
the activity of this ubiquitous transcription factor which has been shown to play a crucial role in 
mediating cytokine-induced gene expression (Tak and Firestein, 2001). In light of current trends 
in cannabinoid research, addressing the transcriptional component of this process may contribute 
towards acquiring a clear and valuable understanding of the inflammatory process as well as of 
the role of cannabinoids and cannabinoid receptors in the function of the immune system.  The 
elucidation of such complex events may lead ultimately to new therapeutic approaches that take 
advantage of an intersection not yet fully exploited.  
2. Materials and Methods 
2.1. Drugs and Reagents 
 Tissue culture reagents were obtained from Gibco (Paisley, UK). Other reagents used 
were: WIN55212-2 (Tocris Cookson, Bristol, UK); TNF-α (PeproTech, Ltd, London, UK); Z-
Leu-Leu-Leu-CHO (MG132; Calbiochem, Beeston, Nottingham, UK) and [γ32P]dATP 
(Amersham, UK). 3-(4,5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), 
aprotinin, benzamidin, chymostatin, leupeptin, pepstatin, phenylmethylsulfonyl fluoride (PMSF), 
dithiothreitol (DTT), sodium vanadate, actinomycin D and cycloheximide were purchased from 
Sigma-Aldrich (Pool, UK). The IκB-α rabbit affinity purified polyclonal antibody and anti-rabbit 
immunoglobulin G-horseradish peroxidase (IgG-HRP) conjugated secondary antibody were from 
Biotechnology, UK. Biotinylated mouse anti-human IL-8 monoclonal antibody, streptavidin-
HRP conjugate secondary antibody, tetramethylammonium-benzidine (TMB) and 96-well Nunc-
immunoplates (maxisorpF96) for ELISA detection were from Pharmingen BD (Oxford, UK). 
DNA oligomers containing the NF-κB (GGG GAC TTT CCC) consensus sequences were 
purchased from Promega (Southampton, UK). All other drugs and chemicals were obtained from 
Sigma or BDH and were of the highest analytical grade obtainable. 
2.2. Cell culture 
 The HT-29 colon epithelial cell line was obtained from the European Collection of 
Animal Cell Cultures (ECACC, Salisbury, Wiltshire, United Kingdom). Cells were grown in 
McCoy’s 5A medium supplemented with 10% foetal bovine serum and penicillin/streptomycin 
(50U/ml and 50µg/ml respectively) plus amphotericin B (0.5µg/ml). Cultures were maintained in 
75cm2 culture flasks at 37ºC in a 5% CO2 humidified tissue culture incubator.  
2.3. Plating of cells for experimentation 
 Confluent monolayers were subdivided and plated at a density of 5 x 105cells/ml in T75 
tissue culture flasks. To detach the monolayer from the flasks, cells were washed once with 
sterile phosphate buffered saline (PBS) and incubated for approximately 5 min in the presence of 
0.25% trypsin/ethylene diamine tetracetic acid (EDTA). Once detached, the action of trypsin was 
stopped by adding 5 ml of McCoy’s 5A containing 10% foetal bovine serum. Cells were diluted 
to the appropriate density, plated and incubated as described.  
 Prior to each experiment cells were washed twice with warm sterile PBS and the 
incubation medium replaced with fresh serum-free McCoy’s medium. All experiments were 
carried out in the absence of serum.  
2.4. Enzyme linked immunosorbent assay for IL-8 release 
 TNF-α-induced IL-8 release from HT-29 cells was determined by ELISA. Confluent cells 
grown in 24-well plates as described above were pre-incubated in the presence of appropriate 
drugs for varying time periods depending on the experimental protocol. Cells were then activated 
with TNF-α (100ng/ml) for 24h. At the end of the incubation time supernatants were collected 
and stored at -20ºC until the assay was performed. 96-well Nunc-immunoplates were coated 
overnight with 1µg/ml anti-human IL-8 monoclonal capture antibody. Plates were subsequently 
washed three times with washing buffer (phosphate buffered saline plus 0.05% Tween 20) and 
blocked with assay diluent (phosphate buffered saline plus 10% foetal bovine serum) for 1h at 
room temperature. After three washes, standards and samples (supernatants diluted 1/10 in 
serum-free medium) were added and incubated at room temperature for 2h. Standard and 
samples were discarded and plates were washed five times with washing buffer. Detection was 
performed in a single step by incubating the plates in the presence of a biotinylated anti-human 
IL-8 antibody and streptavidin linked peroxidase conjugate (each at 0.5µg/ml respectively). After 
incubation for 1h plates were washed seven times and TMB was used as a substrate to quantify 
the amount of bound conjugate by colorimetric measurement.  Absorbance was read at a 
wavelength of 450 nm using a Multiskan II plate reader and the values obtained converted using 
an IL-8 standard curve constructed in parallel. 
2.5. Western blot analysis of IκB-α expression 
Lysates for Western blot analysis were prepared from cells following various 
experimental conditions. Protein concentrations were determined using bicinchoninic acid 
(BCA) reagents according to the instructions provided by the manufacturer. Western blotting 
was carried out as described by Cirino et al. (1996). Briefly, 2µl of 2% bromophenol blue and 
5µl of stock β-mercaptoethanol were added to the samples and heated at 95ºC prior to loading 
20µg of protein onto a sodium dodecyl sulfate (SDS)-polyacrylamide gel (8%). After separation, 
proteins were transferred for 2h at 0.8 mA cm-2 onto a polyvinyldene difluoride (PVDF) 
membrane (Amersham, UK). Membranes were blocked for 1h at 37º in 10mM Tris, 100mM 
NaCl, 0.1% (v/v) Tween-20 (STT) buffer (pH 7.4) containing 5% (w/v) of dry non-fat milk and 
incubated with a polyclonal anti-IκB-α antibody for a further 1h at 37ºC. This was followed by 3 
washes with STT buffer prior to incubating with a secondary anti-rabbit polyclonal IgG 
conjugated with horseradish peroxidase (dilution 1:5000 in STT buffer containing 5% (w/v) dry 
non-fat milk). Membranes were subsequently washed with STT buffer and the immunoreactive 
bands visualized using the enhanced chemiluminescence detection system.  
 
2.6. Electromobility shift assay (EMSA) 
 Changes in the activation of NF-κB under different experimental conditions were 
determined by electromobility shift assays (EMSAs). Confluent HT-29 monolayers in T75 tissue 
cultures flasks were treated as required. Cells were then washed with ice-cold PBS and lysed in 
1ml of lysis buffer consisting of: Tris-HCl (10mM, pH 7.5), MgCl2 (1.5mM), KCl (10mM) and 
NP-40 (0.5%) supplemented with 1.5µg/ml of aprotinin, benzamidine, chymostatin, leupeptin 
and pepstatin, plus phenylmethylsulphonylfluoride (PMSF; 0.2mM), DTT (0.5mM) and sodium 
vanadate (10µM). Lysates were transferred into 1.5ml eppendorff tubes and centrifuged at 4ºC 
for 5 min at 3290xg. Nuclear fractions were subsequently treated with 0.5ml of the above lysis 
buffer. The lysate was centrifuged at 4ºC for 5 min at 3290xg and the supernatant discarded. The 
nuclear pellet was further lysed in 50µl buffer containing Tris-HCl (20mM, pH 7.5), MgCl 
(1.5mM), NaCl (420mM), EDTA (0.2mM), Glycerol (10%) plus the cocktail of protease 
inhibitors described above. After incubation on a platform rotator for 45 min lysates were 
centrifuged at 13147xg for 15 min at 4ºC and the supernatants diluted in 50µl buffer containing 
Tris-HCl (20mM, pH 7.5), MgCl (1.5mM), EDTA (0.2mM), Glycerol (10%) plus the cocktail of 
protease inhibitors. Samples were stored at –80ºC for subsequent use in EMSAs.  
 
 DNA oligomer containing the NF-κB (GGG GAC TTT CCC) consensus sequence was 
end-labeled with [γ32P]dATP. Typically, 10µCi radioactive nucleotide (1µl of 10 mCi/ml) was 
used to label 3.5 pM of oligonucleotide (2µl of 1.75pmol/µl stock) by incubation at 37ºC in the 
presence of 1µl of T4 polynucleotide kinase (T4 PNK) in 1µl of 10X T4 Polynucleotide Kinase 
Buffer (Tris HCl (pH 7.6, 700mM), MgCl2 (100mM) and DTT (50 mM)). The final volume was 
made up to 10µl with 5µl autoclaved H2O. Nuclear extracts (10µg) were incubated with 1µl of 
the labeled probe in 2µl of binding buffer (20% glycerol, 5mM MgCl2, 2.5mM EDTA, 2.5mM 
DTT, 250mM NaCl, 50mM Tris-HCl (pH 7.5), and 0.25mg/ml poly(dI-dC)●poly(dI-dC)) for 40 
min on ice. Samples were subsequently mixed with 1µl of 10X loading buffer (250mM Tris-HCl 
(pH 7.5), 0.2% bromophenol blue and 40% glycerol) before loading onto a 4% acrylamide non-
denaturing gels and run at 130V for 2h. Gels were dried and autoradiographed for analysis.  
 
2.7. Cell viability assay 
Cells in 96-well plates were treated under corresponding experimental conditions and 
incubated with 100µg MTT for 2h at 37ºC, 5% CO2, in standard culture medium. The medium 
was subsequently aspirated and purple formazan crystals solubilised in 100µl of isopropanol. 
The extent of reduction of MTT to formazan within cells was quantified by measurement of 
OD550 using a Multiskan II plate reader.  
 
2.8. Statistical analysis  
Unless specified, all results are expressed as percentage of IL-8 released by TNF-α 
(100ng/ml) treated cells and are the mean ± S.E.M. of at least 3 separate experiments. Statistical 
significance was calculated by analysis of variance (ANOVA) followed by Dunnett’s post hoc 
test. Differences were taken to be statistically significant when P<0.05.  
 
3. Results 
3.1. TNF-α dependent up-regulation of IL-8 release 
Previous studies have shown that unstimulated HT-29 cells express low basal levels of 
IL-8 which can be increased in a time-dependent manner following stimulation of cells (Ihenetu 
et al., 2003a). Consistent with this observation, our initial studies confirm that treatment of HT-
29 cells with TNF-α (10-1000ng/ml) for 24h results in a concentration-dependent increase in the 
levels of IL-8 released into the culture medium (Fig. 1). At the submaximal concentration of 
100ng/ml, TNF-α significantly increased IL-8 release from a basal value of 890 ± 91pg/ml to 
12250 ± 147pg/ml (P<0.05). This concentration was therefore used in all subsequent experiments 
to avoid using high cytotoxic concentrations of this cytokine which may be observed following 
prolonged incubations with 1000ng/ml.  
 
3.2. Effects of MG132, cycloheximide and actinomycin D on TNF-α-induced IL-8 release  
 
 In order to establish whether the stimulatory effects of TNF-α on IL-8 release was due to 
the activation of NF-κB, induced gene transcription and de novo protein synthesis, experiments 
were carried out examining the effects of the proteasomal inhibitor MG132, the inhibitor of gene 
transcription actinomycin D and the protein synthesis inhibitor cycloheximide on TNF-α induced 
IL-8 release. In these studies, cells were pre-treated with each drug for 30 min prior to 
stimulation with TNF-α. The data obtained (Fig. 2) show that TNF-α induced IL-8 release was 
significantly attenuated by MG132 (3µM), actinomycin D (10µM) and by cycloheximide 
(10µM) which respectively inhibited IL-8 release by 76 ± 0.7%, 95 ± 3% and 80 ± 1.6%. 
3.3. Degradation of IκB-α and activation of NF-κB by TNF-α 
The data with MG132 strongly suggests that activation of NF-κB by TNF-α may be 
critical for the induction of IL-8 release. To substantiate this hypothesis, additional experiments 
were carried out examining the effects of TNF-α on both IκB-α degradation and on NF-κB-DNA 
binding activity. Treatment of HT-29 cells with TNF-α (100ng/ml) resulted in a time-dependent 
reduction in IκB-α protein which was evident after 10 min, reaching a maximum at 15 min and 
staying at this depleted level over 30 min before returning to pre-stimulated basal levels after 1h 
(Fig. 3).  
 
In parallel studies, NF-κB-DNA binding was found to be minimal in nuclear extracts 
from control cells but increased after 10 min of exposure to TNF-α and remained at this elevated 
level for up to 1h after activation. This increase in NF-κB-DNA binding was significantly 
inhibited by a 10-fold excess of unlabelled NF-κB-specific oligonucleotide indicating the 
specificity of binding (Fig. 4). 
 
3.4. Effects of the cannabinoid receptor agonist WIN55212-2 on TNF-α induced IL-8 release 
 To confirm that cannabinoids regulate IL-8 release, HT-29 cells were pre-incubated with 
the potent cannabinoid CB1/CB2 receptor agonist WIN55212-2 (10-10 to 10-4M) for 2 h prior to 
activation with TNF-α (100ng/ml)  for 24 h. As shown in Fig. 5, WIN55212-2 exerted a 
concentration-related inhibition of TNF-α induced secretion of  IL-8, completely abolishing the 
latter at 10-5M and inhibiting by approximately 70% at 10-6 M (P<0.01, n=6). 
 
In parallel experiments, addition of WIN55212-2 (10-6 M) either simultaneously with or 
at different intervals after activation of cells with TNF-α (100ng/ml) failed to cause any 
significant change in TNF-α-induced IL-8 release. In these studies, levels of IL-8 remained 
unaltered with respect to the control TNF-α activated cells (Fig. 6). 
 
3.5. Effects of WIN55212-2 on TNF-α induced NF-κB activation and IκB-α degradation 
Effects of WIN55212-2 on the activation of NF-κB was examined in samples prepared 
from cells pretreated for 2h with increasing concentrations of WIN55212-2 (10-9 to 10-4 M) prior 
to activation with TNF-α (100ng/ml) for 1h. In these series of experiments, there were very little 
detectable NF-κB-DNA complexes formed by nuclear extract from control non-activated cells. 
In contrast, incubation of nuclear extracts from TNF-α activated cultures with the 32P labeled κB 
oligonucleotide exhibited increased DNA binding activity which, as shown previously in Fig. 4, 
was virtually abolished by a 10-fold excess of unlabelled NF-κB-specific oligonucleotide. More 
importantly, WIN55212-2 significantly inhibited TNF-α induced NF-κB-DNA binding, virtually 
abolishing the latter at 10-5M. A significant inhibition was also observed with 10-6 M 
WIN55212-2 with lower concentrations (≤10-7 M) having little or no effect (Fig. 7). In parallel 
with the changes in NF-κB-DNA binding activity, TNF-α-induced degradation of IκB-α was also 
inhibited in a concentration-dependent manner by WIN55212-2. As shown in Fig. 8, WIN55212-
2 completely restored IκB-α protein expression back to basal levels at 10-5 M with 10-6 M 
showing partial inhibition of the degradation of IκB.  
 
4. Discussion 
The molecular mechanisms by which cannabinoids exert their broad range of biological 
effects have still not been fully elucidated. One key area of progress in this field is the common 
understanding that regulation of adenylate cyclase may be critical for cannabinoid-mediated 
immunosuppression (Schatz et al., 1992;  Diaz et al., 1993; Kaminski et al.,1994; Kaminski, 
1998). Although, the precise role of cAMP signaling in immune regulation is still not well 
defined, there are indications that this may occur via down regulation of protein kinase A (PKA) 
through inhibition of cAMP production which may in turn suppress binding of CREB/ATF 
transcription factors to the cAMP response element (CRE) consensus motif (Koh et al., 1997; 
Herring et al., 1998; Herring and Kaminski, 1999). Additionally, cannabinoids acting in part 
through suppression of PKA may inhibit activation of NF-kB (Jeon et al., 1996; Herring et al., 
1998; Herring and Kaminski, 1999). It is worth noting however that these actions may be 
cannabinoid and/or cell specific since in mouse thymocytes, cannabinol-induced inhibitions of 
CREB/ATF-1 phosphorylation and NF-κB-DNA binding activity could not be reversed by the 
membrane permeable analogue of cAMP, dibutyryl cAMP (DBcAMP), nor by the potent PKA 
inhibitor N-(2-[ p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide (H89; Herring et al., 
2001). Moreover, in mast cells, CB1 ligands cause an accumulation rather than inhibition in 
cytosolic cAMP levels (Small-Howard et al., 2005) while in mouse dendritic cells, exposure to 
∆9-tetrahydrocannabinol (∆9-THC) induced phosphorylation of IκB-α and enhanced NF-κB 
activation (Do et al., 2004).  
 
Despite the vast literature on the immunosuppressive actions of cannabinoids, there is 
currently little data on the molecular mechanisms that may account for the actions of these 
compounds in modulating IL-8 release by other pro-inflammatory mediators. Attempts were 
therefore made in the current studies to elucidate the molecular mechanism responsible for the 
suppression of TNF-α-induced IL-8 release by WIN55212-2 in the human colon epithelial cell 
line HT-29. Stimulation of these cells with TNF-α for 24h caused a concentration-dependent 
increase in IL-8 production which was significantly inhibited by WIN55212-2. This finding is 
consistent with the inhibition by WIN55212-2 of IL-8 release in human astrocytes (Curran et al., 
2005) and further supports our previous study that demonstrated the greater efficacy of 
WIN55212-2 over other cannabinoid receptor agonists in suppressing TNF-α induced IL-8 
release in HT-29 cells (Ihenetu et al., 2003a).  
 
Interestingly, the above data contrast with reports in the promyelocytic cell line HL60 
where (-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) 
cyclohexanol (CP-55940; Jbilo et al., 1999; Kishimoto et al., 2004) and 2-Arachidonoylglycerol 
(Kishimoto et al., 2004) were shown to enhance IL-8 mRNA and protein expression in a CB2 
dependent manner. The precise reasons for these paradoxical actions of different cannabinoids 
on IL-8 release are unclear and may be governed by several factors, including the cannabinoid in 
question; the cell types used and even the status of the cells being experimented upon. In this 
context, it has been reported that cannabinol may induced IL-2 production in partially activated 
T-cells but decrease the same process when the cells are optimally activated (Jan and Kaminski, 
2001). This highlights the complex nature of the cellular actions of cannabinoids and may 
warrant caution in interpreting results from one system to the next. It is important to emphasising 
however that the immunosuppressive action of WIN55212-2 is a widely reported phenomenon 
which is not restricted to the inhibition of IL-8 alone. WIN55212-2 has also been shown to 
reduce LPS-induced TNF-α production in human peripheral blood mononuclear cells (Germain 
et al., 2002), rat cortical microglial cells (Facchinetti et al., 2003), bronchoalveolar lavage fluid 
(Berdyshev et al., 1998), and inhibits interleukin-2 (IL-2) release from human peripheral blood 
mononuclear cells (Ihenetu et al., 2003b) and from mouse splenocytes (Kaplan et al., 2003). 
Moreover, such actions are common with other cannabinoids including ∆9-THC, which like 
WIN55212-2 also suppressed LPS-induced TNF-α levels in bronchopulmonary inflammation in 
mice (Berdyshev et al., 1998) and reduced LPS-induced mRNAs for IL-1 and TNF-α in neonatal 
rat microglial cells (Puffenbarger et al., 2000). Similarly, suppression of IL-2 release has been 
reported with anandamide (Rockwell and  Kaminski, 2004), cannabinol (Herring and Kamisky, 
1999; Hering et al., 2001) and 2-arachidonyl-glycerol (Ouyang et al., 1998). 
 
The inhibitory effects of WIN55212-2 in our studies were critically dependent on the 
time of addition of the compound prior to activation of cells. Maximal effects were observed 
when WIN55212-2 was added before TNF-α and allowed to equilibrate with cells before they 
were being activated. In contrast, application of WIN55121-2 together with or up to 9h after 
TNF-α failed to cause any significant change in induced IL-8 production. This may be due to the 
combination of a slow action of WIN55212-2 and a quick activation by TNF-α of the NF-κB 
signaling cascade. It is possible that in this case, WIN55212-2 maybe acting through 
mechanisms that trigger events such as new protein synthesis which take time to occur. 
Activation of the cascade may well be initiated after a brief exposure to WIN55212-2 but the 
changes may not occur for hours as is usual for events dependent on changes in cellular and/or 
nuclear signal transduction pathways. Thus it is not surprising that without pre-treatment, 
WIN55212-2 was not able to modify TNF-α induced IL-8 release. These findings are not unique 
to our studies since other reports have indicated that WIN55212-2 may require prolonged 
incubation with tissue to produce its maximal effect. For instance in a study by Tyler et al. 
(2000) WIN55212-2 required between 50–70 min to exert maximal inhibitory effects on mucosal 
transport of fluids and electrolytes across the gastrointestinal tract of the rat. Similar observations 
were also made for other cannabinoids acting on the mouse vas deferens and the myenteric 
plexus preparation of guinea-pig small intestine (Pertwee et al., 1992), and in a study on human 
astrocytes, WIN55212-2 was incubated with the cells for 24 h prior to initiating induction of NO 
production with IL-1-β (Sheng et al., 2005). 
 
Previous studies showed that the IL-8 promoter contains consensus sequences for  NF-κB 
(Casola et al., 2002). To determine the involvement of this transcription factor in the regulation 
of TNF-α induced IL-8 release in HT-29 cells, the profiles of activation of NF-κB was 
determined. Two approaches were taken, the first being to monitor changes in basal IκB-α levels 
by Western blotting and the second to directly measure changes in NF-κB-DNA activity using 
EMSAs. Under normal physiological conditions, NF-κB is sequestrated in the cytoplasm in an 
inactive form as a NF-κB-IκB complex which may be activated through phosphorylation of the 
inhibitory IκB subunit by IκB kinases (IKK; Mercurio et al., 1997; Regnier et al., 1997; Zandi et 
al., 1997). Phosphorylation of IκB results in its ubiquitination and subsequent degradation by the 
ATP-dependent proteolytic 26S proteasome (Palombella et al., 1994) with the consequential 
release of NF-κB which then translocate to the nucleus. As a result, basal levels of IκB are 
usually depleted by agents that activate NF-κB. Consistent with this notion, exposure of HT-29 
cells to TNF-α in our studies resulted in a time-dependent degradation of the IκB-α which was 
relatively rapid in onset, taking approximately 15 min to reach a maximum and remained 
depleted for up to an hour before returning to the pre-stimulated levels. This profile is consistent 
with the rapid but transient activation of the NF-κB pathway due to an auto-regulatory feedback 
loop that allows activated NF-κB to mediate upregulation of IκB-α and in turn switch off any 
signal production (Ghosh et al., 1998)   
 
The decreases in IκB levels observed in our studies correlated well with the activation of 
NF-κB which, once in the nucleus, binds to its corresponding response element on the promoter 
of its target gene and initiates transcription. Electromobility shift assays revealed that NF-κB-
DNA binding was prominent after 10 min reaching a peak at 15 min and sustained for up to an 
hour. Thus, it is clear that TNF-α may stimulate signaling cascades that lead to the activation of 
NF-κB and this may subsequently result in IL-8 release. Confirmation of this being the case was 
obtained in studies employing the potent proteasomal inhibitor MG132 which is known to block 
the degradation of IκB (Palombella et al., 1994). When employed, MG132 caused a distinct 
inhibition of TNF-α-induced IL-8 release from HT-29 cells indicating that the latter process 
requires activation of NF-κB. Consistent with the concept of induced gene transcription and de 
novo protein synthesis are the additional data obtained with actinomycin D and with the protein 
synthesis inhibitor cycloheximide. Pre-treatment with either compound prior to stimulation with 
TNF-α produced a significant inhibition of IL-8 release, indicating that the release of IL-8 
requires de novo protein synthesis and not a mere release of the protein from pre-existing 
intracellular stores. 
 
To address whether WIN55212-2 was able to suppress induced IL-8 release through 
inhibition of NF-κB, studies were carried out examining the effects of this cannabinoid on TNF-
α-induced activation of the NF-κB/IκB pathway in HT-29 cells. In these experiments, Western 
blot analysis of IκB-α expression and NF-κB-DNA binding studies showed that WIN55212-2 
was able to inhibited TNF-α-induced degradation of IκB-α and subsequently NF-κB-DNA 
binding. Moreover, these effects occurred over the same concentration range that inhibited IL-8 
release and were both maximal at the highest concentrations of used (10-5 M), with significant 
inhibition of both processes seen at 10-6 M WIN55212-2.  
 
In summary, our data provide strong evidence that the cannabinoid WIN55212-2 is able 
to regulate IL-8 released by inhibiting the activation of NF-κB in HT-29 cells. This effect may be 
mediated via the cannabinoid CB2 and not the CB1 receptors since our previous studies have 
demonstrated that inhibition of TNF-α-induced IL-8 release by WIN55212-2 could be prevented 
by the potent CB2 receptor antagonist SR144528 but not by the CB1 receptor antagonist 
SR141716A (Ihenetu et al., 2003a). At present, we cannot rule out that other novel receptors or 
indeed effects independent of cannabinoid receptors may be involved in the actions of 
WIN55212-2. This is particularly pertinent in light of recent reports showing that WIN55212-2 
could inhibit IL-1 signalling in human astrocytes independently of cannabinoid receptor 
activation (Curran et al., 2005). Although this issue remains to be clarified, our data addressing 
the molecular mechanisms for some of the immunomodulatory properties of cannabinoids have a 
number of implications. Firstly our findings contribute towards a better understanding of the 
molecular mechanism of actions of cannabinoids and would help unfold the signaling events 
implicated in the immune response. Secondly, our data may provide the basis for the 
development of novel therapeutic strategies that may be beneficial in inflammatory disease states 
associated with the overproduction of cytokines, including IL-8. 
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Figure Legends 
Fig. 1. TNF-α induced release of IL-8 from HT-29 cells. Confluent monolayers of cells were 
stimulated with increasing concentrations of TNF-α (10-1000ng/ml) for 24h. IL-8 release was 
measured by ELISA as described in methods. Data represent means ± S.E.M. of three separate 
experiments. * denotes P<0.01. 
 
Fig. 2. Effect of MG132, actinomycin D and cycloheximide on TNF-α induced IL-8 release 
in HT-29 cells. Confluent monolayers of cells were treated with either MG132 (3µM), 
actinomycin D (10 µM) or cycloheximmide (10 µM) for 30 min prior to stimulation with TNF-α 
(100ng/ml) for 24h. Data are expressed as percentage of inhibition with respect to the TNF-α 
activated controls and represent means ± S.E.M. of three separate experiments. 
 
Fig. 3. Time course of TNF-α induced IκB degradation in HT-29 cells. Confluent monolayers 
of cells were stimulated with TNF-α (100ng/ml) at 37ºC for the indicated times. Levels of IκB 
were determined by Western blotting using a specific monoclonal antibody as described in 
methods. The blot is representative of three separate experiments. 
Fig. 4. Time course of TNF-α induced NF-κB activation in HT-29 cells. Nuclear extracts 
(10µg per lane) were prepared from cells treated with TNF-α (100ng/ml) as described in 
methods. Nuclear proteins were probed in EMSAs with 32P labeled κB oligomer and 
autoradiographed. The blot is representative of three separate experiments. CC: extract from cold 
competition with unlabelled probe; C: extract from control non-activated cells. 
 
Fig. 5. Effect of WIN55212-2 on TNF-α induced IL-8 release in HT-29 cells. Confluent 
monolayers of cells were incubated for 2h in the presence of increasing concentrations of 
WIN55212-2 prior to stimulation with TNF-α (100ng/ml) for 24h. IL-8 release was measured by 
ELISA as described in methods. Data represent means ± S.E.M. of six separate experiments. 
*denotes P<0.01. 
 
Fig. 6. Effect of WIN55212-2 on IL-8 release in TNF-α pre-stimulated HT-29 cells. 
Confluents monolayers of cells were activated with TNF-α (100ng/ml) and WIN55212-2 (10-6 
M) added at the time points indicated post-activation. Supernatants were collected 24h after 




Fig. 7. Effect of WIN55212-2 on TNF-α induced NF-κB activation in HT-29 cells. Nuclear 
extracts were prepared from confluent cultures pre-treated for 2h with WIN55212-2 prior to 
activation with TNF-α (100ng/ml) for 1h. Nuclear proteins were probed with 32P labeled κB 
oligomer and autoradiographed. C: non-activated control; A: TNF-α activated control. The blot 
is representative of three separate experiments. 
 
Fig. 8. Effect of WIN55212-2 on TNF-α induced IκB degradation in HT-29 cells. Cell lysates 
were prepared from cultures pre-treated with WIN55212-2 for 2h prior to activation with TNF-α  
(100ng/ml) for 30 min. Levels of IκB were determined by Western blotting using a specific 
monoclonal antibody as described in methods. C: non-activated control; A: TNF-α activated 
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